We’ve made a few mistakes in the past two years, when it comes to developing COVID drugs. Some were obvious and could have easily been avoided.
Academic rigor, journalistic flair
Articles on Drug development
Displaying 1 - 20 of 77 articles
Substances found in algae, squid and fish all have potential antiviral properties.
If no action is taken to address antibiotic resistance, infections from multidrug-resistant bacteria could cause 10 million deaths each year by 2050.
Ivermectin has been a lifesaving drug for people with parasitic infections like river blindness and strongyloidiasis. But taking it for COVID-19 may result in the opposite effect.
Dave MacMillon and Ben List both developed simple catalysts that make precise chemical reactions much faster and more efficient.
The path to using old drugs for COVID is full of potholes. So why are we using the same old flawed methods when we actually know what works?
Artificial cells on tiny microfluidic chips can provide early insight into how new cancer drugs behave in cells, and why certain kinds of cancer are more resistant to chemotherapy treatment.
‘Orphan drugs’ with high price points are being tested as treatments for COVID-19. There’s a better way to spur low-cost innovation for new drugs.
Whether you are predicting the outcome of an election or studying how effective a new drug is, there will always be some uncertainty. A margin of error is how statisticians measure that uncertainty.
The development of multiple vaccines against the virus that causes COVID-19 has been hailed as the breakthrough of 2020. But there were many more supporting discoveries that made this possible.
Understanding how cells grow under a variety of conditions is necessary for diagnosing disease and developing treatments in the future.
Will a vaccine for COVID-19 be safe? Animal testing, human clinical trials and post-approval surveillance give us good grounds to believe that a future approved vaccine will work and be safe.
Scientists have developed and tested a new anti-clotting drug in mice that shows promise for treating heart attacks and stroke. It may also prove useful for COVID-19.
Word that the U.S. has bought up the entire supply of the COVID-19 drug remdesivir is another reminder that in a pandemic, treatments and vaccines need to be accessible to everyone, globally.
Treatment nationalism is a threat to us all.
It usually takes 10 years for a new vaccine to complete clinical trials, but we’ve been promised a COVID-19 vaccine in 12 to 18 months. Even if such fast-tracked development is possible, is it wise?
Drug repurposing represents our only hope for the treatment of COVID-19 in the short term. But quick and rigorous trials need to be run to provide evidence these drugs work.
Half of all patients who died of COVID-19 in Wuhan had a secondary infection.
If the coronavirus is a lock, a drug to defeat it is a key that needs to fit just right.
Canada is investing millions to develop COVID-19 treatments, but there are no safeguards to ensure that those vaccines and medications will be affordable and accessible to the people who need them.
Top contributors
-
Prof. Institute for Molecular Bioscience, The University of Queensland
-
Professor of Neuroscience, Lancaster University
-
Associate Professor of History, University of Wollongong
-
Associate professor, UNSW
-
Biostatistician, The University of Melbourne
-
Senior Lecturer Biostatistics and Data Management, The University of Queensland
-
Associate Professor of Biostatistics, Murdoch Children's Research Institute
-
Lyn Gilbert is a Friend of The Conversation.
Clinical Professor in Medicine and Infectious Diseases, Marie Bashir Institute for Infectious Diseases and Biosecurity, University of Sydney
-
Professor of Bioethics & Medicine, Sydney Health Ethics, Haematologist/BMT Physician, Royal North Shore Hospital and Director, Praxis Australia, University of Sydney
-
Emeritus Professor of Medical Ethics, The University of Queensland
-
Associate professor, The University of Melbourne
-
Adjunct Professor, Australian Centre for Health Law Research, School of Law, Queensland University of Technology
-
Executive General Manager Commercialisation and Research Contracts, Baker Heart and Diabetes Institute
-
Senior Fellow at Research for Social Change, University of Wollongong
-
Distinguished Writer In Residence, Arthur Carter Journalism Institute, New York University
